• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.

作者信息

Döhner Hartmut, Müller-Tidow Carsten, Lübbert Michael, Fiedler Walter, Krämer Alwin, Westermann Jörg, Bug Gesine, Schlenk Richard F, Krug Utz, Goeldner Rainer-Georg, Hilbert James, Taube Tillmann, Ottmann Oliver G

机构信息

Department of Internal Medicine III, University of Ulm, Ulm, Germany.

Department of Medicine A, University Hospital Muenster, Muenster, Germany.

出版信息

Br J Haematol. 2019 May;185(3):583-587. doi: 10.1111/bjh.15563. Epub 2018 Nov 19.

DOI:10.1111/bjh.15563
PMID:30450591
Abstract
摘要

相似文献

1
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.一项I期试验，研究极光激酶B抑制剂BI 811283联合阿糖胞苷用于急性髓性白血病患者的情况。
Br J Haematol. 2019 May;185(3):583-587. doi: 10.1111/bjh.15563. Epub 2018 Nov 19.
2
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.极光A激酶抑制剂阿利西替尼联合诱导化疗治疗急性髓系白血病患者的I期研究。
Haematologica. 2017 Apr;102(4):719-727. doi: 10.3324/haematol.2016.158394. Epub 2016 Dec 29.
3
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.地西他滨与阿糖胞苷序贯给药用于复发或难治性急性髓性白血病儿童的1-2期安全性、疗效及药代动力学研究
Br J Haematol. 2019 Aug;186(3):e7-e11. doi: 10.1111/bjh.15847. Epub 2019 Mar 7.
4
Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.极光 B 抑制剂巴利塞替尼联合阿糖胞苷对急性髓系白血病细胞具有增效作用。
Cancer Sci. 2013 Jul;104(7):926-33. doi: 10.1111/cas.12164. Epub 2013 May 12.
5
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.利用AZD2811纳米颗粒优化极光激酶B抑制在急性髓系白血病中的治疗效果
Mol Cancer Ther. 2017 Jun;16(6):1031-1040. doi: 10.1158/1535-7163.MCT-16-0580. Epub 2017 Mar 14.
6
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.三联血管激酶抑制剂尼达尼布联合小剂量阿糖胞苷治疗老年急性髓系白血病的I期剂量递增研究
PLoS One. 2016 Oct 7;11(10):e0164499. doi: 10.1371/journal.pone.0164499. eCollection 2016.
7
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.索拉非尼联合标准疗法与安慰剂联合标准疗法治疗 60 岁及以下初诊急性髓系白血病患者（SORAML）：一项多中心、2 期、随机对照试验。
Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.
8
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.一项关于伏司泊达（PSC 833）联合柔红霉素和阿糖胞苷逆转初治老年急性髓系白血病患者多药耐药性的剂量探索性研究。
Hematol J. 2000;1(6):411-21. doi: 10.1038/sj.thj.6200050.
9
Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.在单药或联合阿糖胞苷治疗急性髓系白血病患者中，伏立康唑的群体药代动力学。
Clin Pharmacokinet. 2018 Mar;57(3):379-392. doi: 10.1007/s40262-017-0566-9.
10
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.大剂量米托蒽醌联合阿糖胞苷治疗急性白血病患者的I期临床和药代动力学评估
J Clin Oncol. 1993 Oct;11(10):2002-9. doi: 10.1200/JCO.1993.11.10.2002.

引用本文的文献

1
Histone lactylation-boosted AURKB facilitates colorectal cancer progression by inhibiting HNRNPM-mediated PSAT1 mRNA degradation.组蛋白乳酰化增强的AURKB通过抑制HNRNPM介导的PSAT1 mRNA降解促进结直肠癌进展。
J Exp Clin Cancer Res. 2025 Aug 11;44(1):233. doi: 10.1186/s13046-025-03498-1.
2
Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat.阿利塞替布和巴瑞替尼通过与BH3模拟物和帕比司他序贯联合，在多发性骨髓瘤中诱导细胞周期停滞和线粒体相关的细胞死亡，并增强疗效。
Cancers (Basel). 2025 Jul 9;17(14):2290. doi: 10.3390/cancers17142290.
3
The two sides of chromosomal instability: drivers and brakes in cancer.
染色体不稳定性的两面：癌症中的驱动因素和刹车。
Signal Transduct Target Ther. 2024 Mar 29;9(1):75. doi: 10.1038/s41392-024-01767-7.
4
Aurora B Inhibitors as Cancer Therapeutics.极光 B 抑制剂作为癌症治疗药物。
Molecules. 2023 Apr 11;28(8):3385. doi: 10.3390/molecules28083385.
5
Discovery of a novel Aurora B inhibitor GSK650394 with potent anticancer and anti- dual efficacies .发现一种新型 Aurora B 抑制剂 GSK650394，具有强大的抗癌和双重功效。
J Enzyme Inhib Med Chem. 2022 Dec;37(1):109-117. doi: 10.1080/14756366.2021.1975693.
6
Second-Generation Antimitotics in Cancer Clinical Trials.癌症临床试验中的第二代抗有丝分裂药物。
Pharmaceutics. 2021 Jul 2;13(7):1011. doi: 10.3390/pharmaceutics13071011.
7
Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.极光激酶 B 抑制：癌症的一种潜在治疗策略。
Molecules. 2021 Apr 1;26(7):1981. doi: 10.3390/molecules26071981.